FDA OK’s Allergan’s beauty drug
March 21, 2017Allergan has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURETM XC, for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21.
The company said that in the US pivotal clinical trial, a majority (59%) of subjects saw improvement in moderate to severe nasolabial folds for up to 18 months. Additionally, patient satisfaction in the pivotal study was also high: 82% of patients said they were very satisfied at 6 months and 68% at 18 months.
“The FDA approval of JUVÉDERM VOLLURETM XC demonstrates Allergan’s imperative to develop next-generation HA fillers designed to meet different patient needs,” said David Nicholson, Chief Research and Development Officer at Allergan.
